Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem

Vladimir Svetnik, Raffaele Ferri, Shubhankar Ray, Junshui Ma, James K. Walsh, Ellen Snyder, Bjarke Ebert, Steve Deacon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To evaluate cyclic alternating pattern (CAP) in a phase advance model of transient insomnia and the effects of gaboxadol and zolpidem. Design: A randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h. Setting: 6 sleep research laboratories in US Participants: 55 healthy subjects (18-57 y) Interventions: Gaboxadol 15 mg (GBX), zolpidem 10 mg (ZOL), and placebo (PBO). Measurements: Routine polysomnographic (PSG) measures, CAP, spectral power density, and self-reported sleep measures Results: The phase advance model of transient insomnia produced significant changes in CAP parameters. Both GBX and ZOL significantly and differentially modified CAP parameters in the direction of more stable sleep. GBX brought the CAP rate in stage 1 sleep and slow wave sleep (SWS) closer to baseline levels but did not significantly change the CAP rate in stage 2. ZOL reduced the CAP rate in stage 2 to near baseline levels, whereas the CAP rate in stage 1 and SWS was reduced substantially below baseline levels. The CAP parameter A1 index (associated with SWS and sleep continuity) showed the highest correlation with self-reported sleep quality, higher than any traditional PSG, spectral, or other self-reported measures. Conclusion: Disruptions in CAP produced by phase advanced sleep were significantly and differentially modulated by gaboxadol and zolpidem. The relative independence of CAP parameters from other electrophysiological measures of sleep, their high sensitivity to sleep disruption, and their strong association with subjective sleep quality suggest that CAP variables may serve as valuable endpoints in future insomnia research.

Original languageEnglish
Pages (from-to)1562-1570
Number of pages9
JournalSleep
Volume33
Issue number11
Publication statusPublished - Nov 1 2010

Fingerprint

Sleep
Sleep Initiation and Maintenance Disorders
zolpidem
gaboxadol
Sleep Stages
Research
Cross-Over Studies
Healthy Volunteers
Placebos

Keywords

  • CAP
  • Extrasynaptic GABA agonist
  • Gaboxadol
  • Phase advance
  • Spectral analysis
  • Transient insomnia
  • Zolpidem

ASJC Scopus subject areas

  • Physiology (medical)
  • Clinical Neurology

Cite this

Svetnik, V., Ferri, R., Ray, S., Ma, J., Walsh, J. K., Snyder, E., ... Deacon, S. (2010). Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem. Sleep, 33(11), 1562-1570.

Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem. / Svetnik, Vladimir; Ferri, Raffaele; Ray, Shubhankar; Ma, Junshui; Walsh, James K.; Snyder, Ellen; Ebert, Bjarke; Deacon, Steve.

In: Sleep, Vol. 33, No. 11, 01.11.2010, p. 1562-1570.

Research output: Contribution to journalArticle

Svetnik, V, Ferri, R, Ray, S, Ma, J, Walsh, JK, Snyder, E, Ebert, B & Deacon, S 2010, 'Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem', Sleep, vol. 33, no. 11, pp. 1562-1570.
Svetnik, Vladimir ; Ferri, Raffaele ; Ray, Shubhankar ; Ma, Junshui ; Walsh, James K. ; Snyder, Ellen ; Ebert, Bjarke ; Deacon, Steve. / Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem. In: Sleep. 2010 ; Vol. 33, No. 11. pp. 1562-1570.
@article{435cbbf4ada44268b289392a045b677e,
title = "Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem",
abstract = "Objective: To evaluate cyclic alternating pattern (CAP) in a phase advance model of transient insomnia and the effects of gaboxadol and zolpidem. Design: A randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h. Setting: 6 sleep research laboratories in US Participants: 55 healthy subjects (18-57 y) Interventions: Gaboxadol 15 mg (GBX), zolpidem 10 mg (ZOL), and placebo (PBO). Measurements: Routine polysomnographic (PSG) measures, CAP, spectral power density, and self-reported sleep measures Results: The phase advance model of transient insomnia produced significant changes in CAP parameters. Both GBX and ZOL significantly and differentially modified CAP parameters in the direction of more stable sleep. GBX brought the CAP rate in stage 1 sleep and slow wave sleep (SWS) closer to baseline levels but did not significantly change the CAP rate in stage 2. ZOL reduced the CAP rate in stage 2 to near baseline levels, whereas the CAP rate in stage 1 and SWS was reduced substantially below baseline levels. The CAP parameter A1 index (associated with SWS and sleep continuity) showed the highest correlation with self-reported sleep quality, higher than any traditional PSG, spectral, or other self-reported measures. Conclusion: Disruptions in CAP produced by phase advanced sleep were significantly and differentially modulated by gaboxadol and zolpidem. The relative independence of CAP parameters from other electrophysiological measures of sleep, their high sensitivity to sleep disruption, and their strong association with subjective sleep quality suggest that CAP variables may serve as valuable endpoints in future insomnia research.",
keywords = "CAP, Extrasynaptic GABA agonist, Gaboxadol, Phase advance, Spectral analysis, Transient insomnia, Zolpidem",
author = "Vladimir Svetnik and Raffaele Ferri and Shubhankar Ray and Junshui Ma and Walsh, {James K.} and Ellen Snyder and Bjarke Ebert and Steve Deacon",
year = "2010",
month = "11",
day = "1",
language = "English",
volume = "33",
pages = "1562--1570",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "11",

}

TY - JOUR

T1 - Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem

AU - Svetnik, Vladimir

AU - Ferri, Raffaele

AU - Ray, Shubhankar

AU - Ma, Junshui

AU - Walsh, James K.

AU - Snyder, Ellen

AU - Ebert, Bjarke

AU - Deacon, Steve

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Objective: To evaluate cyclic alternating pattern (CAP) in a phase advance model of transient insomnia and the effects of gaboxadol and zolpidem. Design: A randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h. Setting: 6 sleep research laboratories in US Participants: 55 healthy subjects (18-57 y) Interventions: Gaboxadol 15 mg (GBX), zolpidem 10 mg (ZOL), and placebo (PBO). Measurements: Routine polysomnographic (PSG) measures, CAP, spectral power density, and self-reported sleep measures Results: The phase advance model of transient insomnia produced significant changes in CAP parameters. Both GBX and ZOL significantly and differentially modified CAP parameters in the direction of more stable sleep. GBX brought the CAP rate in stage 1 sleep and slow wave sleep (SWS) closer to baseline levels but did not significantly change the CAP rate in stage 2. ZOL reduced the CAP rate in stage 2 to near baseline levels, whereas the CAP rate in stage 1 and SWS was reduced substantially below baseline levels. The CAP parameter A1 index (associated with SWS and sleep continuity) showed the highest correlation with self-reported sleep quality, higher than any traditional PSG, spectral, or other self-reported measures. Conclusion: Disruptions in CAP produced by phase advanced sleep were significantly and differentially modulated by gaboxadol and zolpidem. The relative independence of CAP parameters from other electrophysiological measures of sleep, their high sensitivity to sleep disruption, and their strong association with subjective sleep quality suggest that CAP variables may serve as valuable endpoints in future insomnia research.

AB - Objective: To evaluate cyclic alternating pattern (CAP) in a phase advance model of transient insomnia and the effects of gaboxadol and zolpidem. Design: A randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h. Setting: 6 sleep research laboratories in US Participants: 55 healthy subjects (18-57 y) Interventions: Gaboxadol 15 mg (GBX), zolpidem 10 mg (ZOL), and placebo (PBO). Measurements: Routine polysomnographic (PSG) measures, CAP, spectral power density, and self-reported sleep measures Results: The phase advance model of transient insomnia produced significant changes in CAP parameters. Both GBX and ZOL significantly and differentially modified CAP parameters in the direction of more stable sleep. GBX brought the CAP rate in stage 1 sleep and slow wave sleep (SWS) closer to baseline levels but did not significantly change the CAP rate in stage 2. ZOL reduced the CAP rate in stage 2 to near baseline levels, whereas the CAP rate in stage 1 and SWS was reduced substantially below baseline levels. The CAP parameter A1 index (associated with SWS and sleep continuity) showed the highest correlation with self-reported sleep quality, higher than any traditional PSG, spectral, or other self-reported measures. Conclusion: Disruptions in CAP produced by phase advanced sleep were significantly and differentially modulated by gaboxadol and zolpidem. The relative independence of CAP parameters from other electrophysiological measures of sleep, their high sensitivity to sleep disruption, and their strong association with subjective sleep quality suggest that CAP variables may serve as valuable endpoints in future insomnia research.

KW - CAP

KW - Extrasynaptic GABA agonist

KW - Gaboxadol

KW - Phase advance

KW - Spectral analysis

KW - Transient insomnia

KW - Zolpidem

UR - http://www.scopus.com/inward/record.url?scp=78649841535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649841535&partnerID=8YFLogxK

M3 - Article

C2 - 21102998

AN - SCOPUS:78649841535

VL - 33

SP - 1562

EP - 1570

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 11

ER -